2-47799287-T-C
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000179.3(MSH6):c.1304T>C(p.Leu435Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L435V) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Publications
- intellectual developmental disorder with dysmorphic facies and behavioral abnormalitiesInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 5 Pathogenic:2
This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 22581703]. This variant is expected to disrupt protein structure [Myriad internal data]. -
- -
not provided Pathogenic:1
Published functional studies demonstrate a damaging effect: deficient MMR activity, protein instability, and aberrant splicing (Hampel 2007, Kantelinen 2012); Not observed in large population cohorts (Lek 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32809219, 16885385, 22290698, 23621914, 24811117, 28152038, 22581703, 17909073) -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 435 of the MSH6 protein (p.Leu435Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with endometrial cancer (PMID: 16885385; internal data). It has also been observed to segregate with disease in related individuals. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MSH6 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,370,736 individuals referred to our laboratory for MSH6 testing. ClinVar contains an entry for this variant (Variation ID: 89186). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MSH6 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects MSH6 function (PMID: 22581703). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1304T>C (p.L435P) alteration is located in exon 4 (coding exon 4) of the MSH6 gene. This alteration results from a T to C substitution at nucleotide position 1304, causing the leucine (L) at amino acid position 435 to be replaced by a proline (P). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This mutation has been identified in individuals with endometrial cancer demonstrating microsatellite instability and/or loss of MSH6 protein expression on IHC (Hampel, 2006; Kim, 2020; Ambry internal data). This nucleotide and amino acid position are highly conserved in available vertebrate species. RNA studies demonstrated this mutation resulted in aberrant splicing and skipping of exon 4 (Hampel, 2007). Functional studies also found this variant to be MMR-deficient and unstable when expressed in vitro (Kantelinen, 2012). In silico splice site analysis predicts that this nucleotide alteration will not have any significant effect on splicing. This amino acid alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. -
Endometrial carcinoma Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at